Medibio Limited
Medibio Limited (MDBIF) Financial Performance & Income Statement Overview
Review Medibio Limited (MDBIF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Medibio Limited (MDBIF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Medibio Limited MDBIF financial performance.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $9566.00 | $293.00 | $147.00 |
| Cost of Revenue | $46352.00 | $46781.00 | $1.00 | $1.00 |
| Gross Profit | -$46352.00 | -$37215.00 | $292.00 | $146.00 |
| Gross Profit Ratio | $0.00 | -$3.89 | $1.00 | $0.99 |
| R&D Expenses | $11263.00 | $3011.00 | $90221.00 | $45111.00 |
| SG&A Expenses | $966320.00 | $1.04M | $964038.00 | $157125.00 |
| Operating Expenses | $977583.00 | $1.03M | $1.05M | $1.33M |
| Total Costs & Expenses | $1.02M | $1.07M | $1.33M | $1.33M |
| Interest Income | $0.00 | $2260.00 | $0.00 | $3308.00 |
| Interest Expense | $0.00 | $13873.00 | $3312.00 | $0.00 |
| Depreciation & Amortization | $46352.00 | $46781.00 | $274463.00 | $248116.00 |
| EBITDA | -$977590.00 | -$1.03M | -$416098.00 | -$416098.00 |
| EBITDA Ratio | $0.00 | -$107.37 | -$3597.17 | -$2830.60 |
| Operating Income | -$1.02M | -$1.07M | -$1.33M | -$664214.00 |
| Operating Income Ratio | $0.00 | -$112.26 | -$4533.89 | -$4518.46 |
| Other Income/Expenses (Net) | $872350.00 | -$11613.00 | -$1.32M | -$660709.00 |
| Income Before Tax | -$151590.00 | -$1.09M | -$2.65M | -$1.32M |
| Income Before Tax Ratio | $0.00 | -$113.48 | -$9043.84 | -$9013.08 |
| Income Tax Expense | -$2.00 | $0.00 | -$3.00 | $0.00 |
| Net Income | -$151590.00 | -$1.09M | -$2.65M | -$1.32M |
| Net Income Ratio | $0.00 | -$113.48 | -$9043.84 | -$9013.08 |
| EPS | -$0.001 | -$0.004 | -$0.01 | -$0.007 |
| Diluted EPS | -$0.001 | -$0.004 | -$0.01 | -$0.007 |
| Weighted Avg Shares Outstanding | $309.27M | $306.29M | $181.24M | $181.72M |
| Weighted Avg Shares Outstanding (Diluted) | $309.27M | $306.29M | $181.24M | $197.58M |
The company's financials show resilient growth, with revenue advancing from $147.00 in Q3 2023 to $0.00 in Q4 2024. Gross profit remained healthy with margins at N/A in Q4 2024 compared to 99% in Q3 2023. Operating income hit -$1.02M last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$977590.00. Net income rose to -$151590.00, while earnings per share reached -$0.001. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan